Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.37 |
| ▸ | ABL1 | P00519 | 2/20 | 0.35 |
| ▸ | BCR | P11274 | 2/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1013651 | 0.86 | TRPV1 (0.46) | TRPV1ABL1BCR | |
| SCHEMBL4470661 | 0.79 | MAP3K12 (0.31) | — | |
| SCHEMBL4000057 | 0.77 | DRD2 (0.35) | MAPKAPK2 | |
| SCHEMBL1011713 | 0.77 | TRPV1 (0.46) | TRPV1ABL1BCR | |
| SCHEMBL1012368 | 0.73 | CYP2D6 (0.42) | — | |
| SCHEMBL4000656 | 0.73 | — | — | |
| SCHEMBL3999458 | 0.73 | GSK3B (0.37) | ABL1BCR | |
| SCHEMBL1013535 | 0.72 | TP53 (0.34) | TRPV1 | |
| SCHEMBL1012787 | 0.71 | TRPV1 (0.32) | TRPV1 | |
| Hydrochloric Acid SCHEMBL1016427 | 0.70 | AGPAT2 (0.32) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390907-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-06-24 | — | — | US | claimed |
| EP-1775295-A1 | Vanilloid receptor ligands and their use in treatments | Amgen Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| EP-1670794-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2006-06-21 | — | — | EP | claimed |
| US-20050153984-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-07-14 | — | — | US | claimed |
| WO-2005033105-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2005-04-14 | — | — | WO | claimed |
| US-7390907-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2008-06-24 | — | — | US | disclosed |
| EP-1780211-A2 | Vanilloid receptor ligands and their use in treatments | Amgen Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1775295-A1 | Vanilloid receptor ligands and their use in treatments | Amgen Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20050153984-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153984-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | TRPV1 1/4885ABL1 1564/4885BCR 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.